COMBI-MB

Background

COMBI-MB was a phase II open-label multicenter trial evaluating dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) in patients with BRAF V600-mutant melanoma brain metastases across four prespecified cohorts based on BRAF V600 mutation type, prior local brain therapy, and symptom status. BRAF V600-mutant melanoma comprises ~40–50% of metastatic melanoma; both dabrafenib monotherapy (BREAK-MB) and vemurafenib had shown intracranial activity in earlier trials. COMBI-MB extended this to the combination (dabrafenib + trametinib), which had established superior extracranial OS vs BRAF monotherapy (COMBI-d, COMBI-v).

Interventions and follow up

Regimen: Dabrafenib 150 mg PO BID + trametinib 2 mg PO QD until progression; 4 cohorts: A (V600E, asymptomatic, no prior local therapy, n=76); B (V600E, asymptomatic, prior local therapy, n=16); C (V600E, symptomatic ± steroids, n=16); D (V600D/K/R, n=17)
Primary endpoint: Intracranial response rate (ICR) per blinded IRC (≥30% decrease in sum of longest diameters of target BMs); secondary: duration of intracranial response, extracranial ORR, PFS, OS, safety
mFollow up: 8.5 months (Cohort A, primary analysis)

Results

Cohort A ICR (primary, V600E asymptomatic, no prior BM therapy): 58% (CR 22%, PR 36%)
Cohort A mDuration of intracranial response: 6.5 months
Cohort A mPFS: 5.6 months
Cohort A mOS: 10.8 months
Cohort B ICR: 56%
Cohort C ICR: 44%
Cohort D ICR: 59%
Cohort A extracranial ORR: 55%

Adverse events

Grade ≥3 AEs: 57% (Cohort A)
Pyrexia (dabrafenib-related) Grade ≥3: 10%
Grade ≥3 fatigue: 6%
Grade ≥3 hypertension: 4%
Squamous cell carcinoma (BRAF inhibitor class effect): 4%
Elevated LFTs Grade ≥3: 4%
Grade ≥3 headache/CNS AEs: 4%
Discontinuation due to AEs: 19% (Cohort A); dose reductions 35%; no new unexpected toxicity vs COMBI-d/COMBI-v

Conclusions

Dabrafenib plus trametinib achieved a 58% intracranial response rate with a 22% complete response rate in BRAF V600E-mutant asymptomatic untreated melanoma brain metastases, demonstrating that BRAF+MEK inhibition produces clinically meaningful intracranial responses across all four BRAF V600-mutant subtypes and symptom categories, establishing this combination as a CNS-active targeted therapy for BRAF-mutant melanoma brain metastases.

Key Limitations

Single-arm Phase II — no randomized comparator; relatively short mPFS (5.6 months) and mOS (10.8 months) reflect the natural history of CNS melanoma and the durability limitation of BRAF/MEK inhibition; acquired resistance via MEK pathway reactivation limits response duration; no comparison to nivo+ipi (CheckMate 204 — likely superior for long-term outcomes in asymptomatic patients); mOS 10.8 months markedly inferior to nivo+ipi Cohort A 3-yr OS 52% — suggesting targeted therapy offers faster responses but less durable control; intracranial response by modified RECIST may not capture pseudoprogression; small cohort sizes (B, C, D: n=16–17); short median follow-up at primary analysis; concurrent SRS/WBRT impact on outcomes not fully delineated.

Clinical Context

COMBI-MB establishes that BRAF+MEK inhibitors have meaningful intracranial activity in BRAF V600-mutant melanoma BM, with a faster response time vs immunotherapy — making them preferable for rapidly symptomatic or large BM in BRAF-mutant patients. However, the shorter response durability compared to nivo+ipi means that in asymptomatic neurologically stable patients, nivo+ipi is often preferred for its durable 3-year OS benefit. ASCO/ESMO guidelines recognize both nivo+ipi and BRAF+MEK inhibition for BRAF-mutant melanoma BM, with preference depending on symptomatology and urgency. Triplet therapy (atezolizumab + cobimetinib + vemurafenib; IMspire150) and SRS integration with BRAF+MEK are areas of ongoing development.

References